Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma

Platelet-Derived Growth Factor-Receptor α Strongly Inhibits Melanoma Growth In Vitro and In Vivo

(2015) Debora Faraone et al.   NEOPLASIA

Identification of Potential Serum Biomarkers of Glioblastoma: Serum Osteopontin Levels Correlate with Poor Prognosis

(2010) P. Sreekanthreddy et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Grade-Specific Expression of Insulin-like Growth Factor-Binding Proteins-2, -3, and -5 in Astrocytomas: IGFBP-3 Emerges as a Strong Predictor of Survival in Patients with Newly Diagnosed Glioblastoma

(2010) V. Santosh et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Genetic Screen Identifies Insulin-like Growth Factor Binding Protein 5 as a Modulator of Tamoxifen Resistance in Breast Cancer

(2010) B. Y. Ahn et al.   CANCER RESEARCH

Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines

(2010) Bhaswati Sarcar et al.   JOURNAL OF NEURO-ONCOLOGY

PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment

(2009) Yongping Crawford et al.   CANCER CELL

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

(2009) Evanthia Galanis et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic therapies for high-grade glioma

(2009) Andrew D. Norden et al.   Nature Reviews Neurology

Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas

(2009) Yi Lin et al.   NEURO-ONCOLOGY

IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas

(2009) L. M. Moore et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Insulin-like growth factor-binding protein-5 (IGFBP-5) acts as a tumor suppressor by inhibiting angiogenesis

(2008) Seung Bae Rho et al.   CARCINOGENESIS

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

(2008) Andrew D. Norden et al.   JOURNAL OF NEURO-ONCOLOGY

A role for VEGF as a negative regulator of pericyte function and vessel maturation

(2008) Joshua I. Greenberg et al.   NATURE

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE